Xin Lang Cai Jing·2026-02-26 06:33Group 1 - The core viewpoint of the news highlights the trading performance and financing activities of Spring Medical, indicating a net financing purchase of 271.09 million yuan on February 25, with a total financing and securities balance of 73.01 million yuan [1] - Spring Medical's financing balance of 73.01 million yuan accounts for 1.14% of its circulating market value, which is above the 90th percentile level over the past year, indicating a high level of financing activity [1] - The company has not engaged in any short selling activities on February 25, with a short selling balance of 4458.00 yuan, which is also above the 70th percentile level over the past year, suggesting a relatively high level of short selling interest [1] Group 2 - Spring Medical, established on February 12, 1998, specializes in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prosthetics and spinal implants [2] - The company reported a revenue of 756 million yuan for the period from January to September 2025, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, reflecting a significant increase of 213.21% year-on-year [2] - As of September 30, 2025, the number of shareholders increased by 4.12% to 6164, while the average circulating shares per person decreased by 3.95% to 46906 shares [2] Group 3 - Spring Medical has distributed a total of 440 million yuan in dividends since its A-share listing, with 390 million yuan distributed over the past three years [3] - Among the top ten circulating shareholders as of September 30, 2025, Hong Kong Central Clearing Limited is the fourth largest new shareholder with 2.9585 million shares, while China Europe Economic Selection Mixed A and Ping An Low Carbon Economy Mixed A are also notable new shareholders [3] - South Pharmaceutical Health Flexible Allocation Mixed A has exited the list of the top ten circulating shareholders [3]